DOCSLIB.ORG

Rituximab Induced Serum Sickness Or Immune Complex Deposition Disease: Case Report and Desensitisation Protocol

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Rituximab Induced Serum Sickness Or Immune Complex Deposition Disease: Case Report and Desensitisation Protocol HEMATOCASE 75 Rituximab induced serum sickness or immune complex deposition disease: case report and desensitisation protocol N. Granacher, MD, T. Eyckmans, MD SUMMARY The chimeric monoclonal IgG1 antibody directed to CD20 Rituximab is used to treat various haematological malignancies and auto-immune diseases. Serum sickness is a type III hypersensitivity reaction leading to the formation and tissue deposition of immune antibody-antigen complexes. It has been described as a very rare complication of Rituximab treatment, mainly seen in patients treated for auto-immune diseases. We report the case of a patient with Waldenström’s macroglobulinaemia whose Rituximab treatment was com- plicated by documented immune complex deposition or serum sickness. We successfully applied a Rituximab desensitisation protocol, which allowed us to complete treatment. (BELG J HEMATOL 2020;11(2):75-8) INTRODUCTION to 22.9 g/l. Two weeks later, he experienced mild general Serum sickness is an immune complex-mediated hyper- malaise and arthralgias. These symptoms were self-limiting sensitivity disease or type III allergic reaction to a certain and patient therefore did not consult his treating haemato- antigen in which auto-antibodies bind a foreign antigen and logist. Four weeks after the first treatment cycle he received form immune complexes. Although very rare, it has been a second cycle of Rituximab-Bendamustine. Blood exami- reported in patients treated with Rituximab. nation at start showed normal haematopoiesis and an IgM level of 27 g/l (monoclonal protein concentration 16 g/l). CASE REPORT Previously he had been diagnosed with atrial flutter treated A 73-year old man was diagnosed in 2000 with an IgM with apixaban and bisoprolol. A day after the administration monoclonal gammopathy of undetermined significance of Rituximab the patient experienced intense shivering (IgM MGUS, monoclonal protein of 11.8 g/l). He had no and fever of up to 38,5 degrees Celsius. He was admitted at other comorbidities nor was he taking any medication. Eigh- our ward of haematology for observation. The day after his teen years later, he progressed to a symptomatic MYD88 platelet count significantly dropped (23 x 10^9/l, ref range positive Waldenström’s macroglobulinaemia with signs of 140 - 340 x 10^9/l), LDH levels increased (1400 U/l, ref hyperviscosity (polyneuropathy, dyspnoea and visual dis- range 313 - 618 U/l) and his inflammatory markers were turbances). IgM levels at that time were 42.8 g/l (ref 0.4-2.3 elevated (leucocytosis/neutrophilia and CRP up to 90 mg/l g/l) with monoclonal protein concentration of 36.3 g/l. (ref range <10 mg/l). He complained of general fatigue and Haemoglobin levels and thrombocytes/leukocytes count were arthralgia in the shoulders and hips. Two days later his com- normal. He was immediately treated with plasmapheresis plaints gradually decreased thanks to systemic analgesia after which immuno-chemotherapy (Rituximab 375 mg/m² and the thrombocytopenia slowly recovered (on discharge on day 1 and bendamustine 70 mg/m² on day 1 and 2) was thrombocyte count was 49 x 10^9/l, ref range 140 - 340 x initiated. On discharge (day 3) his IgM levels had dropped 10^9/l). Additional blood examination was able to confirm Department of Haematology, ZNA Stuivenberg, Antwerp, Belgium. Please send all correspondence to: N. Granacher, MD, Haematology, ZNA Stuivenberg (Ziekenhuis Netwerk Antwerp), Lange Beeldeken- straat 267, 2060 Antwerp, Belgium, tel: +32 3 217 72 57, email: [email protected]. Conflict of interest: The authors have nothing to disclose and indicate no potential conflict of interest. Keywords: desensitisation, immune complex deposition disease, rituximab, serum sickness, Waldenström’s macroglobulinaemia. VOLUME11MARCH20202 76 TABLE 1. Rituximab induced serum sickness in haematological malignancies. Reference Patient Diagnosis Dosing Cycle number Time of onset Treatment Demonaco F, 47yr Follicular 375 mg/m² 4th administration Day 7 Steroids (not further et al ³ lymphoma specified) Disperati F, 52yr Follicular 180 mg/m² 5th administration Day 2 Methylprednisolone et al 4 lymphoma Diphenhydramine Meperidine Todd M, 68yr Mantle cell 375 mg/m² 1st administration Day 13 Methylprednisolone et al 5 lymphoma Portlock M, 70yr Follicular 375 mg/m² 1st administration Day 5 Prednisone et al 6 lymphoma Portlock F, 51yr Follicular 375 mg/m² 2nd administration Day 7 Prednisone et al 6 lymphoma Fajt F, 37yr Gastric MALT 375 mg/m² 2nd administration Day 3 Methylprednisolone et al 7 lymphoma Diphenhydramine Matsui Not MALT 375 mg/m² 1st administration Day 9 Steroids (not further et al 8 specified lymphoma specified) Matsui Not Waldenström’s 375 mg/m² 1st administration Day 17 Steroids (not further et al 8 specified macroglobuli- specified) naemia our suspicion of immune complex deposition disease (serum daily and non-steroidal anti-inflammatory drugs (ibuprofen sickness) presumably provoked by Rituximab with documen- 800 mg twice daily) as supporting measures for five days. ted IgG and IgM circulating immune complexes (IgG-CIC Using this protocol Rituximab was successfully administered 29 µg/ml, ref range <25 µg/ml and IgM 33 µg/ml, ref range for the subsequent three cycles (in combination with ben- <11 µg/ml) and hypocomplementemia for C3 and C4 damustin on day 2 and 3). After completion of therapy indicating complement consumption. Ten days later, his patient had a very good partial response with only 5,2 g/l complaints had disappeared and blood results returned to IgM remaining (monoclonal protein concentration 4 g/l). normal. We decided to administer a third cycle of Rituxi- Approximately ten months later, he remains in a very good mab via fractionated subcutaneous injection (two injections partial remission. spread over two administration days) hoping that a slower release of the monoclonal antibody might prevent immune CASE DISCUSSION complex formation. He was also pre-medicated with 100 mg of Serum sickness is an immune complex-mediated hyper- hydrocortisone on day 1. Nevertheless, he developed similar sensitivity disease or type III allergic reaction to a certain complaints of arthralgia and fatigue, albeit postponed and antigen in which auto-antibodies bind a foreign antigen not occurring before day 4. We once again documented the and form immune complexes. The syndrome was initially formation of immune complexes with pronounced LDH rise described in the early 1900’s when it was seen in association (4144 U/l). Thrombocytes dropped to 77 x 10^9/l on day 4. with the use of horse serum containing diphtheria antitoxin. Searching the literature, we found similar cases to ours. We In a normal situation, the antigen-antibody complexes are found a Rituximab desensitisation protocol developed for cleared via phagocytosis however; in serum sickness disease patients with IgE hypersensitivity but successfully used in a this elimination system is either malfunctioning or saturated few patients with documented immune complex deposition by the immune complex load. The remaining immune com- disease. We decided to continue treatment using this desen- plexes deposit in several tissues such as joints and skin. sitisation protocol and added methylprednisolone 32 mg once Clinical features of serum sickness are rash, fever, general VOLUME11MARCH2020 HEMATOCASE 77 FIGURE 1. Rituximab desensitisation protocol adapted from Wong et al.1 Total amount of drug was diluted into 250 cc of NaCl 0,9% for the rapid and intermediate protocol and 1000cc of NaCl 0,9% for the high-risk protocol Serial 10-fold dilutions were made for the rapid (1 dilution) and intermediate (2 dilutions) and high risk protocol (3 dilutions). Rapid protocol Intermediate protocol High-risk protocol Step Time Concentration Infusion Concentration Infusion Concentration Infusion (mg/cc) rate (cc/h) (mg/cc) rate (cc/h) (mg/cc) rate (cc/h) 1 0:00 0,2 5 0,02 2,5 0,0005 20 2 0:15 0,2 10 0,02 5 0,0005 40 3 0:30 0,2 20 0,02 10 0,0005 80 4 0:45 0,2 49 0,02 20 0,005 20 5 1:00 2,0 10 0,2 5 0,005 40 6 1:15 2,0 20 0,2 10 0,005 80 7 1:30 2,0 40 0,2 20 0,05 20 8 RP 1:45 – 4:40 2,0 80 8 other 1:45 0,2 40 0,05 40 9 2:00 2,0 10 0,05 80 10 2:15 2,0 20 0,5 20 11 2:30 2,0 40 0,5 40 12 2:45 2,0 60 60 13 IP 3:00 – 5:45 2,0 80 13 HRP 3:00 – 15:00 0,5 80 malaise, polyarthralgia or even polyarthritis, fever and pro- chronic immune mediated thrombocytopenia, Sjögren’s teinuria occurring 1-2 weeks after first exposure to the disease or SLE).1 Although even more rare Rituximab indu- responsible antigen or occurring within a few days of secon- ced serum sickness has also been reported in patients with dary antigen exposure. Symptoms are generally self-limiting haematological malignancies (namely lymphoproliferative and resolve within weeks after initial exposure to the culprit diseases) indicating that the underlying pathophysiology antigen. The responsible immune complexes can be docu- might be related to, in general, increased antibody production mented in the peripheral blood and most patients have sig- or hypergammaglobulinemia. Table 1 gives an overview of nificant hypocomplementemia characterised by low CH50, patients diagnosed with Rituximab induced serum sickness, C3 and C4. treated for a haematological malignancy (Table 1). Serum sickness associated with Rituximab is a very rare Of the eight patients reported, only 50% experienced serum treatment complication and has only been described in a sickness after the first administration of Rituximab with few case reports, most of them discussing patients with symptoms arising day 5-17 after initial exposure. Symptoms rheumatoid arthritis or other auto-immune diseases (e.g.
Load more

Recommended publications
  • Anti-Thymocyte Globulin (Atg) and Ciclosporin (Csa)
    Myeloid group ANTI-THYMOCYTE GLOBULIN (ATG) AND CICLOSPORIN (CSA) INDICATION ATG and CSA is indicated for patients who require treatment for aplastic anaemia (AA) but who are not eligible for sibling donor BMT. This includes (note references to severity are based on the modified Camitta criteria): Patients with non-severe aplastic anaemia who are dependent on red cell and/or platelet transfusions. Patients with severe aplastic anaemia (SAA) or very SAA who are > 35-50 years of age. Patients with SAA or very SAA disease who lack an HLA-compatible sibling donor. Protocol may be used in selected patients with hypoplastic marrow conditions. Patients with severe AA who are ≤ 35 years old and have a HLA identical sibling donor, should be treated with allogenic bone marrow transplantation as soon as possible after diagnosis. TREATMENT INTENT Prolong survival Provide a rapid (within 3 months) and sustained improvement in peripheral blood counts Restore haematopoiesis PRE-ASSESSMENT 1. ATG should only used by physicians familiar with administering ATG. Medical and nursing teams must be aware of the side effects and how to treat promptly and appropriately. 2. ATG is highly immunosuppressive - only use in centres with at least level 2 facilities. Patients should be nursed in a single or double isolation room, as an inpatient. 3. Risk of transfusion-associated GvHD following treatment with ATG is unclear, therefore irradiated blood components are currently recommended. It is not known how long the use of irradiated products This is a controlled document and therefore must not be changed Page 1 of 9 ML.2 ATG & CSA Authorised by Myeloid Lead Oct 2019 V.4.1 Prof Adam Mead Myeloid group should be continued, but it may be reasonable to continue while patients are still taking CSA following ATG therapy.
    [Show full text]
  • Unintentional Platelet Removal by Plasmapheresis
    Journal of Clinical Apheresis 16:55–60 (2001) Unintentional Platelet Removal by Plasmapheresis Jedidiah J. Perdue,1 Linda K. Chandler,2 Sara K. Vesely,1 Deanna S. Duvall,2 Ronald O. Gilcher,2 James W. Smith,2 and James N. George1* 1Hematology-Oncology Section, Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 2Oklahoma Blood Institute, Oklahoma City, Oklahoma Therapeutic plasmapheresis may remove platelets as well as plasma. Unintentional platelet loss, if not recognized, may lead to inappropriate patient assessment and treatment. A patient with thrombotic thrombocytopenic purpura- hemolytic uremic syndrome (TTP-HUS) is reported in whom persistent thrombocytopenia was interpreted as continuing active disease; thrombocytopenia resolved only after plasma exchange treatments were stopped. This observation prompted a systematic study of platelet loss with plasmapheresis. Data are reported on platelet loss during 432 apheresis procedures in 71 patients with six disease categories using three different instruments. Com- paring the first procedure recorded for each patient, there was a significant difference among instrument types ,than with the COBE Spectra (1.6% (21 ס P<0.001); platelet loss was greater with the Fresenius AS 104 (17.5%, N) .With all procedures, platelet loss ranged from 0 to 71% .(24 ס or the Haemonetics LN9000 (2.6%, N (26 ס N Among disease categories, platelet loss was greater in patients with dysproteinemias who were treated for hyper- viscosity symptoms. Absolute platelet loss with the first recorded apheresis procedure, in the 34 patients who had a normal platelet count before the procedure, was also greater with the AS 104 (2.23 × 1011 platelets) than with the Spectra (0.29 × 1011 platelets) or the LN9000 (0.37 × 1011 platelets).
    [Show full text]
  • Platelet-Rich Plasmapheresis: a Meta-Analysis of Clinical Outcomes and Costs
    THE jOURNAL OF EXTRA-CORPOREAL TECHNOLOGY Original Article Platelet-Rich Plasmapheresis: A Meta-Analysis of Clinical Outcomes and Costs Chris Brown Mahoney , PhD Industrial Relations Center, Carlson School of Management, University of Minnesota, Minneapolis, MN Keywords: platelet-rich plasmapheresis, sequestration, cardiopulmonary bypass, outcomes, economics, meta-analysis Presented at the American Society of Extra-Corporeal Technology 35th International Conference, April 3-6, 1997, Phoenix, Arizona ABSTRACT Platelet-rich plasmapheresis (PRP) just prior to cardiopulmonary bypass (CPB) surgery is used to improve post CPB hemostasis and to minimize the risks associated with exposure to allogeneic blood and its components. Meta-analysis examines evidence ofPRP's impact on clinical outcomes by integrating the results across published research studies. Data on clinical outcomes was collected from 20 pub­ lished studies. These outcomes, DRG payment rates, and current national average costs were used to examine the impact of PRP on costs. This study provides evidence that the use of PRP results in improved clinical outcomes when compared to the identical control groups not receiving PRP. These improved clinical out­ comes result in subsequent lower costs per patient in the PRP groups. All clinical outcomes analyzed were improved: blood product usage, length of stay, intensive care stay, time to extu­ bation, incidence of cardiovascular accident, and incidence of reoperation. The most striking differences occur in use of all blood products, particularly packed red blood cells. This study provides an example of how initial expenditure on technology used during CPB results in overall cost savings. Estimated cost savings range from $2,505.00 to $4,209.00.
    [Show full text]
  • Management of Refractory Autoimmune Hemolytic Anemia Via Allogeneic Stem Cell Transplantation
    Bone Marrow Transplantation (2016) 51, 1504–1506 © 2016 Macmillan Publishers Limited, part of Springer Nature. All rights reserved 0268-3369/16 www.nature.com/bmt LETTER TO THE EDITOR Management of refractory autoimmune hemolytic anemia via allogeneic stem cell transplantation Bone Marrow Transplantation (2016) 51, 1504–1506; doi:10.1038/ urine output and nausea. Physical examination was otherwise bmt.2016.152; published online 6 June 2016 normal. Her laboratory evaluation was notable for a hematocrit of 17%, reticulocyte count of 6.8%, haptoglobin below assay limits and an Waldenström’s macroglobulinemia (WM) represents a subset LDH (lactate dehydrogenase) that was not reportable due to of lymphoplasmacytic lymphomas in which clonally related hemolysis (Table 1). Creatinine was 1.1 mg/dL, total bilirubin was lymphoplasmacytic cells secrete a monoclonal IgM Ab.1 6.7 mg/dL with a direct bilirubin of 0.3 mg/dL and lactate was Overproduced IgMs can act as cold agglutinins in WM. Upon 5 mmol/L. Over 4 h, her hematocrit decreased to 6% and her exposure to cooler temperatures in the periphery, they cause creatinine rose to 1.6 mg/dL. Given concern for acute hemolytic anemia via binding to the erythrocyte Ii-antigen group and anemia due to cold agglutinins, she was warmed and received classical complement cascade initiation.2 Treatment of seven units of warmed, packed RBC, broad-spectrum antibiotics, cold-agglutinin-mediated autoimmune hemolytic anemia (AIHA) high-dose steroids and underwent emergent plasmapheresis. She in WM typically targets the pathogenic B-cell clone1–4 or the also underwent hemodialysis for presumed pigment nephropathy.
    [Show full text]
  • I Have Spots and My Skin Burns
    I have spots and my skin burns Patient presentation History Differential diagnosis Examination Investigations Discussion Treatment Final Outcome References Evaluation - Questions & answers MCQs Patient presentation Peter, a 60 year-old Caucasian policeman, complains of a painful burning sensation in his lower extremities lasting for several months. Lower limbs petechiae (small purple/red hemorrhagic spots) appeared one week ago. Acknowledgement This case study was provided by Prof. Olivier Boyer (M.D., Ph.D., Head of the Department of Immunology and Biotherapy, Rouen University Hospital, France) and Dr. Maëlle Le Besnerais (M.D., Assistant Professor of Internal Medicine, Rouen University Hospital, France) of the Faculty of Medicine of Rouen, Normandy University, France. The authors would like to thank David Saadoun, Odile Goria, Lucie Guyant-Maréchal and Fabienne Jouen for their critical reading of this case study, Isabelle Duval for the development of pictures and Laetitia Demoulins for technical assistance. We are grateful to Nikki Sabourin-Gibbs, Rouen University Hospital, for her help in editing the manuscript. Immunopaedia.org.za History Peter complains of chronic fatigue and aching joints which started several months ago. He denies significant alcohol consumption and intravenous drug abuse. He received a blood transfusion after a gunshot injury to his arm 35 years ago. He reports distal paraesthesia (tingling or numbness) of both legs and painful burning in both feet which has progressed to the lower and upper limbs. Knee pain wakes him up at night. Past medical history None No allergies Surgical history Appendix removed at 10 years old Arm gunshot injury 35 years ago Family history His father has hypertension and type 2 diabetes Travel history He traveled to Thailand 25 years ago Social history Policeman, married, two children Medication None Differential diagnosis IgA vasculitis Polyarteritis nodosa ANCA-associated vasculitis (eg.
    [Show full text]
  • Patient Information Leaflet – Plasma Exchange Procedure
    Therapeutic Apheresis Services Patient Information Leaflet – Plasma Exchange Procedure Introduction Antibodies, which normally help to protect you from infection, can begin to attack your own This leaflet has been written to give patients healthy cells, or an over production of proteins can information about plasma exchange (sometimes cause your blood to become thicker and slow down called plasmapheresis). If you would like any more the blood flow throughout your body. A plasma information or have any questions, please ask the exchange can help improve your symptoms, doctors and nurses involved in your treatment at although this may not happen immediately. the NHS Blood and Transplant (NHSBT) Therapeutic Apheresis Services Unit. Although plasma exchange may help with symptoms, it will not normally cure your condition When you have considered the information given as it does not switch off the production of the in this leaflet, and after we have discussed the harmful antibodies or proteins. It is likely that procedure and its possible risks with you, we will this procedure will form only one part of your ask you to sign a consent form to indicate that you treatment. are happy for the procedure to go ahead. Before any further procedures we will again check that you are happy to proceed. How do we perform Plasma Exchange? What is a plasma exchange? Plasma exchange is performed using a machine Blood is made up of red cells, white cells and called a Blood Cell Separator which can separate platelets which are carried around in fluid called blood into its various parts. The machine separates plasma.
    [Show full text]
  • Penicillin Allergy Guidance Document
    Penicillin Allergy Guidance Document Key Points Background Careful evaluation of antibiotic allergy and prior tolerance history is essential to providing optimal treatment The true incidence of penicillin hypersensitivity amongst patients in the United States is less than 1% Alterations in antibiotic prescribing due to reported penicillin allergy has been shown to result in higher costs, increased risk of antibiotic resistance, and worse patient outcomes Cross-reactivity between truly penicillin allergic patients and later generation cephalosporins and/or carbapenems is rare Evaluation of Penicillin Allergy Obtain a detailed history of allergic reaction Classify the type and severity of the reaction paying particular attention to any IgE-mediated reactions (e.g., anaphylaxis, hives, angioedema, etc.) (Table 1) Evaluate prior tolerance of beta-lactam antibiotics utilizing patient interview or the electronic medical record Recommendations for Challenging Penicillin Allergic Patients See Figure 1 Follow-Up Document tolerance or intolerance in the patient’s allergy history Consider referring to allergy clinic for skin testing Created July 2017 by Macey Wolfe, PharmD; John Schoen, PharmD, BCPS; Scott Bergman, PharmD, BCPS; Sara May, MD; and Trevor Van Schooneveld, MD, FACP Disclaimer: This resource is intended for non-commercial educational and quality improvement purposes. Outside entities may utilize for these purposes, but must acknowledge the source. The guidance is intended to assist practitioners in managing a clinical situation but is not mandatory. The interprofessional group of authors have made considerable efforts to ensure the information upon which they are based is accurate and up to date. Any treatments have some inherent risk. Recommendations are meant to improve quality of patient care yet should not replace clinical judgment.
    [Show full text]
  • Letters to the Editor
    LETTERS TO THE EDITOR Complications of plasma exchange in after percutaneous insertion of a subclavian central ve- thrombotic thrombocytopenic nous catheter from pneumothorax and hemorrhage. Two purpura-hemolytic uremic syndrome: patients suffered cardiac arrest with pulseless electrical a study of 78 additional patients activity: one from an anaphylactic reaction to plasma and The frequency of patients treated with plasma exchange the other from pericardial hemorrhage and tamponade, (PE) for thrombotic thrombocytopenic purpura- presumably due to cardiac perforation by an internal hemolytic uremic syndrome (TTP-HUS) increased seven- jugular catheter insertion guidewire. fold from 1981 to 1997.1 Therefore, the morbidity and Other major catheter-related complications included mortality due to PE is an increasingly important consid- one patient with a retroperitoneal hemorrhage following eration in management decisions for patients with clini- femoral catheter insertion and seven patients with cath- cally suspected TTP-HUS. Some studies have described eter thrombosis that prevented PE and/or required place- few complications associated with PE,2 but our previous ment of a new central venous catheter; two of these seven report on 71 consecutive patients with clinically sus- patients had catheter-related venous thrombosis requir- pected TTP-HUS treated with PE from 1996 to 1999 dem- ing systemic anticoagulation. Ten patients developed sys- onstrated a major complication rate of 30 percent, in- temic infection: eight had blood cultures positive for the cluding two deaths.3 This report describes our experience presence of bacteria (Staphylococcus aureus [five], Staph- during the subsequent 3 years, 1999 to 2002, with 78 con- ylococcus epidermidis [three]); the two patients with secutive patients.
    [Show full text]
  • Hypersensitivity Reactions (Types I, II, III, IV)
    Hypersensitivity Reactions (Types I, II, III, IV) April 15, 2009 Inflammatory response - local, eliminates antigen without extensively damaging the host’s tissue. Hypersensitivity - immune & inflammatory responses that are harmful to the host (von Pirquet, 1906) - Type I Produce effector molecules Capable of ingesting foreign Particles Association with parasite infection Modified from Abbas, Lichtman & Pillai, Table 19-1 Type I hypersensitivity response IgE VH V L Cε1 CL Binds to mast cell Normal serum level = 0.0003 mg/ml Binds Fc region of IgE Link Intracellular signal trans. Initiation of degranulation Larche et al. Nat. Rev. Immunol 6:761-771, 2006 Abbas, Lichtman & Pillai,19-8 Factors in the development of allergic diseases • Geographical distribution • Environmental factors - climate, air pollution, socioeconomic status • Genetic risk factors • “Hygiene hypothesis” – Older siblings, day care – Exposure to certain foods, farm animals – Exposure to antibiotics during infancy • Cytokine milieu Adapted from Bach, JF. N Engl J Med 347:911, 2002. Upham & Holt. Curr Opin Allergy Clin Immunol 5:167, 2005 Also: Papadopoulos and Kalobatsou. Curr Op Allergy Clin Immunol 7:91-95, 2007 IgE-mediated diseases in humans • Systemic (anaphylactic shock) •Asthma – Classification by immunopathological phenotype can be used to determine management strategies • Hay fever (allergic rhinitis) • Allergic conjunctivitis • Skin reactions • Food allergies Diseases in Humans (I) • Systemic anaphylaxis - potentially fatal - due to food ingestion (eggs, shellfish,
    [Show full text]
  • Unique Urticarial Presentation of Minocycline-Induced Lupus
    Volume 23 Number 8 | August 2017 Dermatology Online Journal || Case Report DOJ 23 (8): Unique urticarial presentation of minocycline-induced lupus erythematosus Ashley K Clark1, Vivian Y Shi2 MD, Raja K Sivamani3,4 MD MS CAT Affiliations: 1School of Medicine, University of California, Davis, Sacramento, CA USA, 2Department of Medicine, Division of Dermatology, University of Arizona, Tucson, USA, 3Department of Dermatology, University of California, Davis, Sacramento, CA USA, 4Department of Biological Sciences, California State Univeristy, Sacramento, CA USA Corresponding Author: Raja Sivamani, MD MS CAT, Department of Dermatology, University of California, Davis, 3301 C Street, Suite 1400, Sacramento, CA 95816, Tel: 916-703-5145, Fax: 916-734-7183, Email: [email protected] Abstract with minocycline-induced lupus (MIL) typically present with fever and polyarthralgia, ANA positivity, We present a 17-year-old boy who developed a and elevated erythrocyte sedimentation rate, but generalized urticarial eruption, malar rash, fever, and negative levels of antihistone antibodies (AHAs) arthralgia within one week of initiating minocycline and anti-native DNA antibodies [4, 5]. Our report therapy for acne. His workup showed positive anti- highlights an unusual urticarial presentation of MIL nuclear and anti-histone antibodies. His symptoms with rapid resolution after oral prednisone. To the best quickly resolved after discontinuing minocycline and of our knowledge there is only one case of DIL with starting oral prednisone. We believe the constellation an urticarial presentation. The purpose of this report of his symptoms, laboratory findings, and temporal is to increase recognition of a unique presentation of association of minocycline initiation was suggestive DIL following minocycline treatment.
    [Show full text]
  • Recommendations for Collecting Red Blood Cells by Automated Apheresis Methods
    Guidance for Industry Recommendations for Collecting Red Blood Cells by Automated Apheresis Methods Additional copies of this guidance document are available from: Office of Communication, Training and Manufacturers Assistance (HFM-40) 1401 Rockville Pike, Rockville, MD 20852-1448 (Tel) 1-800-835-4709 or 301-827-1800 (Internet) http://www.fda.gov/cber/guidelines.htm U.S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research (CBER) January 2001 Technical Correction February 2001 TABLE OF CONTENTS Note: Page numbering may vary for documents distributed electronically. I. INTRODUCTION ............................................................................................................. 1 II. BACKGROUND................................................................................................................ 1 III. CHANGES FROM THE DRAFT GUIDANCE .............................................................. 2 IV. RECOMMENDED DONOR SELECTION CRITERIA FOR THE AUTOMATED RED BLOOD CELL COLLECTION PROTOCOLS ..................................................... 3 V. RECOMMENDED RED BLOOD CELL PRODUCT QUALITY CONTROL............ 5 VI. REGISTRATION AND LICENSING PROCEDURES FOR THE MANUFACTURE OF RED BLOOD CELLS COLLECTED BY AUTOMATED METHODS.................. 7 VII. ADDITIONAL REQUIREMENTS.................................................................................. 9 i GUIDANCE FOR INDUSTRY Recommendations for Collecting Red Blood Cells by Automated Apheresis Methods This
    [Show full text]
  • Utility of Double Filtration Plasmapheresis in Acute Antibody
    doi: 10.5262/tndt.2011.1003.17 Olgu Sunumu/Case Report Utility of Double Filtration Plasmapheresis in Acute Antibody Mediated Renal Allograft Rejection: Report of Three Cases Akut Antikor Aracılı Renal Allograt Rejeksiyonunda Çift Filtrasyon Plazmaferez: Üç Vaka Bildirimi ABSTRACT Yalçın SOLAK1 Hüseyin ATALAY1 Plasmapheresis is an extracorporeal procedure, which is often employed to rapidly lower circulating 2 titers of autoantibodies, immune complexes or toxins. There are two types of plasmapheresis namely, İlker POLAT 1 regular plasmapheresis (RPP) by centrifugation and membrane fi ltration, and double fi ltration Melih ANIL 1 plasmapheresis (DFPP) which is a special form of membrane fi ltration in which two membranes called Kültigin TÜRKMEN 1 as plasma separator and plasma fractionator are employed to fi lter macromolecules more selectively. Zeynep BIYIK 1 DFPP have several advantages over RP. Despite widespread utilization of DFPP in the setting of ABO Mehdi YEKSAN blood group incompatible kidney transplantation, there is no report regarding DFPP in patients with antibody mediated acute renal allograft rejection who are good candidates for benefi cial effects of DFPP. Here we report three renal transplant recipients in whom DFPP was applied as a component of anti-rejection treatment regimen. 1 Selcuk University Faculty of Medicine, KEYWORDS: Kidney, Transplantation, Rejection, Plasmapheresis Department of Nephrology, Konya, Turkey 2 Selcuk University Faculty of Medicine, ÖZ Department of Internal Medicine, Konya, Turkey Plazmaferez, dolaşımdaki antikor, immün kompleks ve toksin düzeylerini hızla düşürmek için kullanılan bir ekstrakorporeal yöntemdir.İki tip plazmaferez bulunmaktadır: Santrifüj ve membran fi ltrasyonu ile yapılan regüler plazmaferez (RP) ve büyük moleküllerin daha selektif olarak fi ltre edildiği, plazma ayırıcısı ve plazma fraksiyoneri olarak adlandırılan iki membranın kullanıldığı özel bir fi ltrasyon şekli olan çift fi ltrasyon plazmaferezdir (ÇFP).ÇFP’nin RP’ye göre bazı avantajları vardır.
    [Show full text]